Cost-effectiveness analysis of toripalimab combined with nab-paclitaxel as a first-line treatment for advanced TNBC in the US
Our analysis suggests that, from a US health care system perspective, toripalimab in combination with chemotherapy does not demonstrate a significant cost-effective advantage over nab-P chemotherapy as a first-line treatment for patients with TNBC at a WTP threshold of $100,000/QALY and has a limited impact on US health care policy and clinical practice.
Authors
- Rong Tian (ORCID: https://orcid.org/0000-0002-5191-9004)
- Guohua Deng (ORCID: https://orcid.org/0000-0003-0804-1117)
- Liping Xiao (ORCID: https://orcid.org/0000-0002-9763-3001)
- Qing Yang (ORCID: https://orcid.org/0000-0002-9641-3170)
- Ping Chen (ORCID: https://orcid.org/0009-0004-7791-8757)
- Dan Qiao (ORCID: https://orcid.org/0000-0003-2375-1512)
Institutions
- Sichuan Cancer Hospital (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1371/journal.pone.0320727
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Department of Science and Technology of Sichuan Province